Across TCGA pan-cancer cohorts, CEACAM8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEACAM8 data layer compared with 23 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEACAM8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEACAM8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.
LUAD, UCEC, and PDAC are the cancer types where CEACAM8 mass-spec protein most reproducibly stratifies survival.